Colinz Laboratories Ltd
Colinz Laboratories Ltd (COLINZ) last reported results for the quarter ended Jun 2026, with sales of ₹1.24 crore and net profit of ₹2.4 crore. The stock last traded at ₹73, a market capitalisation of ₹18.4 crore, on a P/E of 36.8. Over the past 52 weeks the stock has ranged between ₹36.1 and ₹87.9. Figures are as of 6 Oct 2026 and are not real time.
Colinz Laboratories Ltd share price and key metrics
- Current price
- ₹73
- Market cap
- ₹18.4 cr
- Stock P/E
- 36.8
- Book value
- ₹39.9
- ROE
- 5.23%
- ROCE
- 7.20%
- Dividend yield
- 0.00%
- 52w high / low
- 87.9/36.1
Metrics as of 6 Oct 2026. Not real time.
Track Colinz Laboratories Ltd
Cruxal reads every Colinz Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Colinz Laboratories Ltd growth and returns
- 10 Years
- -3%
- 5 Years
- 0%
- 3 Years
- -5%
- TTM
- -9%
- 10 Years
- 19%
- 5 Years
- 19%
- 3 Years
- 2%
- TTM
- 4%
- 10 Years
- 16%
- 5 Years
- 27%
- 3 Years
- 24%
- 1 Year
- 71%
- 10 Years
- 4%
- 5 Years
- 5%
- 3 Years
- 5%
- Last Year
- 5%
Colinz Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹1.24 cr, down 21.0% from ₹1.57 cr a year earlier. Net profit was ₹2.4 cr, up 1900.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1.86 | 1.47 | 1.45 | 1.57 | 1.39 | 1.43 | 1.75 | 1.24 |
| Expenses | 1.69 | 1.4 | 1.35 | 1.44 | 1.31 | 1.33 | 1.66 | 1.18 |
| Operating profit | 0.17 | 0.07 | 0.1 | 0.13 | 0.08 | 0.1 | 0.09 | 0.06 |
| OPM % | 9.14% | 4.76% | 6.90% | 8.28% | 5.76% | 6.99% | 5.14% | 4.84% |
| Other income | 0.08 | 0.08 | 0.08 | 0.08 | 0.16 | 0.08 | 0.17 | 2.89 |
| Interest | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Profit before tax | 0.21 | 0.11 | 0.13 | 0.16 | 0.19 | 0.13 | 0.21 | 2.9 |
| Tax % | 23.81% | 45.45% | -23.08% | 25.00% | 26.32% | 30.77% | 19.05% | 17.24% |
| Net profit | 0.16 | 0.05 | 0.15 | 0.12 | 0.14 | 0.08 | 0.17 | 2.4 |
| EPS (₹) | 0.64 | 0.20 | 0.60 | 0.48 | 0.56 | 0.32 | 0.67 | 9.53 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Colinz Laboratories Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8.05 | 7.83 | 7.59 | 7.53 | 6.16 | 6.97 | 7.15 | 7.03 | 6.53 | 6.14 | 5.81 |
| Operating profit | 0.41 | 0.35 | 0.35 | 0.31 | 0.34 | 0.59 | 0.63 | 0.54 | 0.49 | 0.42 | 0.33 |
| OPM % | 5.09% | 4.47% | 4.61% | 4.12% | 5.52% | 8.46% | 8.81% | 7.68% | 7.50% | 6.84% | 5.68% |
| Net profit | 0.14 | 0.23 | 0.12 | 0.13 | 0.21 | 0.34 | 0.46 | 0.49 | 0.5 | 0.51 | 2.79 |
| EPS (₹) | 0.31 | 0.50 | 0.26 | 0.28 | 0.46 | 0.74 | 1.83 | 1.95 | 1.98 | 2.02 | 11.08 |
TTM is the trailing twelve months to the most recent quarter.
Colinz Laboratories Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 3.54 | 3.54 | 3.54 | 3.54 | 3.55 | 3.55 | 2.52 | 2.52 | 2.52 | 2.52 |
| Reserves | 2.98 | 3.21 | 3.30 | 3.29 | 3.75 | 4.14 | 5.62 | 6.43 | 6.96 | 7.52 |
| Borrowings | 0.76 | 0.42 | 0.68 | 0.38 | 0.99 | 0.48 | 0.27 | 0.57 | 0.64 | 0.39 |
| Other liabilities | 2.40 | 2.42 | 1.65 | 1.60 | 1.81 | 1.76 | 1.82 | 1.84 | 1.70 | 2.35 |
| Total liabilities | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 11.82 | 12.78 |
| Fixed assets | 2.63 | 2.41 | 2.21 | 2.06 | 2.03 | 1.86 | 1.71 | 1.58 | 1.70 | 1.54 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.41 | 0.53 | 0.50 | 0.36 | 0.61 | 0.67 | 0.66 | 1.02 | 1.04 | 1.11 |
| Other assets | 6.64 | 6.65 | 6.46 | 6.39 | 7.46 | 7.40 | 7.86 | 8.76 | 9.08 | 10.13 |
| Total assets | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 11.82 | 12.78 |
As reported by the company. Total assets equal total liabilities by construction.
Colinz Laboratories Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0.06 | 0.34 | 0.12 | 0.58 | 2.16 | 0.47 | 0.40 | 1.03 | -1.45 | 2.54 |
| Cash from investing | -0.01 | -0.11 | -0.01 | -0.04 | -0.16 | -0.03 | 0.01 | 0.01 | -0.23 | 0.01 |
| Cash from financing | -0.03 | 0.01 | 0.02 | 0.06 | 0.08 | 0.09 | 0.11 | 0.23 | 0.24 | 0.43 |
| Net cash flow | 0.02 | 0.24 | 0.12 | 0.60 | 2.07 | 0.52 | 0.52 | 1.27 | -1.45 | 2.98 |
| Free cash flow | 0.04 | 0.34 | 0.12 | 0.54 | 2.00 | 0.43 | 0.40 | 1.03 | -1.71 | 2.54 |
| CFO / operating profit | 22% | 106% | 43% | 210% | 659% | 105% | 89% | 224% | -253% | 650% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Colinz Laboratories Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 3.00% | 3.18% | 3.40% | 3.39% | 4.39% | 6.80% | 8.08% | 7.70% | 6.62% | 7.20% |
| Debtor days | 66.65 | 78.31 | 80.79 | 72.22 | 77.03 | 63.36 | 57.69 | 44.65 | 36.89 | 49.93 |
| Inventory days | 267.25 | 266.31 | 246.80 | 225.13 | 208.33 | 147.59 | 149.17 | 134.31 | 136.22 | 148.55 |
| Days payable | 55.68 | 91.93 | 44.16 | 49.29 | 90.00 | 76.17 | 103.15 | 94.81 | 94.31 | 80.64 |
| Cash conversion cycle | 278.23 | 252.70 | 283.42 | 248.06 | 195.36 | 134.78 | 103.71 | 84.15 | 78.81 | 117.84 |
| Working capital days | 71.19 | 72.72 | 89.45 | 79.01 | 0.00 | 9.95 | 11.23 | -22.84 | 73.22 | -60.64 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Colinz Laboratories Ltd shareholding pattern
Promoters held 50.60% at Jun 2026, down from 66.00% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 66.00% | 66.00% | 66.00% | 66.00% | 66.00% | 66.00% | 66.00% | 50.60% |
| Public | 34.00% | 33.99% | 33.99% | 34.00% | 33.99% | 34.00% | 34.00% | 49.39% |
| No. of shareholders | 3,116 | 3,202 | 3,216 | 3,238 | 3,272 | 3,212 | 3,250 | 3,174 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Colinz Laboratories Ltd corporate filings
- Dear Sir, PFA, The Compliance Certificate issued by our RTA for Sep-26 under regulation 74(5). Kindly take the same on records . For Colinz Labs Ltd DirectorCompany Updatelow impact
- Colinz Laboratories Limited declares non-applicability of SEBI Regulation 32 for Q2 FY2027, indicating no recent public or rights issueCompany Updatelow impact
Cruxal's analysis: Colinz Laboratories Limited has issued a communication confirming that Regulation 32 of…
Read the full analysis - Colinz Laboratories Ltd declares non-applicability of related party transactions for Q2 2026Company Updatelow impact
Cruxal's analysis: The company has issued a certificate stating that Regulation 23(9) of SEBI (LODR)…
Read the full analysis - We would like to inform you that pursuant to the COmpanys Act and SEBI(PIT), Regulation, 2015 The Trading Window for Designated Persons and KMPS will remain closed form 1-10-26 to till ....Insider Trading / SASTlow impact
- Colinz Laboratories Limited announces successful conclusion of 40th Annual General Meeting and approval of all resolutionsAGM/EGMlow impact
Cruxal's analysis: Colinz Laboratories Limited has formally concluded its 40th Annual General Meeting held…
Read the full analysis - Colinz Laboratories Limited concludes 40th Annual General Meeting; reappoints key management personnelAGM/EGMlow impact
Cruxal's analysis: Colinz Laboratories Limited has successfully concluded its 40th Annual General Meeting…
Read the full analysis - Colinz Laboratories Limited Announces 40th Annual General Meeting and Book Closure DatesCompany Updatelow impact
Cruxal's analysis: Colinz Laboratories Limited has issued a formal notice for its 40th Annual General…
Read the full analysis - Colinz Laboratories Ltd files 40th Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Colinz Laboratories Ltd has submitted its 40th Annual Report for the financial year…
Read the full analysis - Colinz Laboratories Ltd announces book closure dates for E-votingCorp. Actionlow impact
Cruxal's analysis: Colinz Laboratories Ltd has notified the closure of its books from 15-09-2026 to…
Read the full analysis - Colinz Laboratories Limited Announces 40th AGM and Board Re-appointmentsAGM/EGMlow impact
Cruxal's analysis: Colinz Laboratories Limited has scheduled its 40th Annual General Meeting for 22nd…
Read the full analysis - Colinz Laboratories Limited: Promoters Announce Open Offer for 26% Stake at INR 54 per ShareCompany Updatehigh impact
Cruxal's analysis: Colinz Laboratories Limited is the subject of an open offer by the Dugar family (Annjana…
Read the full analysis - Colinz Laboratories Limited: Acquirers Announce Open Offer for 26% Stake at INR 54 per ShareCompany Updatehigh impact
Cruxal's analysis: Colinz Laboratories Limited is the subject of an open offer by Annjana Dugar, Likhitta…
Read the full analysis - Colinz Laboratories Ltd publishes newspaper advertisement regarding Independent Director declarationsCompany Updatelow impact
Cruxal's analysis: Colinz Laboratories Ltd has submitted a newspaper clipping dated August 5, 2026…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.